Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
C CARDIOVASCULAR SYSTEM
C01 CARDIAC THERAPY
C01C CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
C01CA Adrenergic and dopaminergic agents
C01CA27 Droxidopa
D01277 Droxidopa (JP18/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Cardiovascular Agents
Alpha-adrenergic Agonists
Droxidopa
D01277 Droxidopa (JP18/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
116 Antiparkinsonian agents
1169 Others
D01277 Droxidopa (JP18/USAN/INN)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01967 Antiparkinson agent
D01277 Droxidopa
Drug classes [BR:br08332]
Neuropsychiatric agent
DG01967 Antiparkinson agent
D01277 Droxidopa
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Adrenaline
ADRA1
D01277 Droxidopa (JP18/USAN/INN) <JP/US>
ADRA2
D01277 Droxidopa (JP18/USAN/INN) <JP/US>
ADRB
D01277 Droxidopa (JP18/USAN/INN) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D01277 Droxidopa
D01277 Droxidopa capsules
D01277 Droxidopa fine granules
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D01277
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D01277